Trials / Completed
CompletedNCT02791269
A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Expanded Access Program of PEGASYS® (Peg Interferon Alpha-2a 40 KD) in Patients With HBeAg-Positive And HBeAg-Negative Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV infection. All participants will receive 48 weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | 180 mcg SC injection QW for 48 weeks. |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2016-06-06
- Last updated
- 2017-02-06
- Results posted
- 2017-02-06
Locations
6 sites across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT02791269. Inclusion in this directory is not an endorsement.